-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。バイオマリンは、2026年第1四半期決算で、売上高7億6,600万ドル（前年同期比3%増）と市場予想を1,400万ドル上回るものの、非GAAPベースの1株当たり利益（EPS）は0.76ドル（前年同期比33%減）となり、市場予想の0.91ドルを下回りました。この四半期は、NAGLAZYMEの製造費用3,100万ドルとAmicus買収費用が影響しました。48億ドル規模のAmicus買収は4月に完了し、GALAFOLDとPOMBILITI + OPFOLDAが加わり、バイオマリンの希少疾患ポートフォリオが拡大しました。経営陣は、2026年の売上高見通しを38億2,500万ドル～39億2,500万ドルに引き上げ、中間値で前年同期比20%増となる見込みです。 2026年には、ENPP1欠損症に対するBMN 401の第3相試験結果や、軟骨低形成症に対するVOXZOGOの第3相試験データが第2四半期に発表されるなど、複数のパイプラインの触媒となる要素が期待されており、これらはいずれも2026年下半期の規制当局への申請を後押しする可能性があります。当社では、BMRNは2026年の売上高の55%以上が下半期に集中すると予想しており、これによりEPSの認識が後半に集中すると考えています。20億ドルの現金と第1四半期の営業キャッシュフロー2億2100万ドルを有するBioMarinは、当社としては、十分な財務上の柔軟性を維持していると考えています。
Related Articles
Asia
Lottery Secures Agreement for 40-Year License Extension
Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.
$ASX:TLC
Asia
Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%
Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.
$ASX:GTK$NZE:GTK
Research
Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.
$VRTX